Improving targeted radiation therapy for prostate cancer using personalized dosimetry and biomarkers
Official title: Enhancing radioligand therapy for prostate cancer with biomarker and dosimetry guided personalization
Funded at University of Michigan at Ann Arbor · NIH-10857881 · Data updated 2026-11-12
This study is looking to improve treatment for advanced prostate cancer by customizing radiation therapy based on each patient's unique needs, using special imaging to determine the best dose for their tumors while keeping side effects low.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 17, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $644,622 |
| NIH project number | 1R01CA289631-01 |
| Project ID | NIH-10857881 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic castrate resistant prostate cancer who are eligible for radioligand therapy.
✕Less likely to help
Patients with early-stage prostate cancer or those not eligible for radioligand therapy may not benefit from this research.
What this research studies
This research focuses on enhancing radioligand therapy for metastatic castrate resistant prostate cancer by personalizing treatment based on individual patient characteristics. It utilizes advanced imaging techniques to estimate the absorbed dose of radiation to tumors and critical organs, allowing for tailored dosing strategies. By analyzing pre-therapy imaging and adjusting the dosage for the first treatment cycle, the goal is to maximize the effectiveness of the therapy while minimizing potential side effects. Patients will be monitored closely to assess the impact of these personalized approaches on treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer radiation treatments for prostate cancer patients.
How similar studies have gone: Previous research has shown promising results with personalized approaches in radiation therapy, suggesting potential for success in this novel application.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Dewaraja, Yuni K — University of Michigan at Ann Arbor
- Study coordinator: Dewaraja, Yuni K
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.